I had so much fun doing FierceBiotech's executive breakfast in Boston last October that I've decided to take the show on the road. Everybody in the Bay Area and the near-beyond listen up. On April 13, I'll be hosting FierceBiotech's first executive breakfast of the year at the Hotel Nikko in downtown San Francisco. Our topic: How can you improve your odds at running an ideal Phase II study?
We've lined up several top clinical executives for the panel discussion: Mathai Mammen, the co-founder and SVP of R&D at Theravance, which is allied with GlaxoSmithKline on Relovair, a promising late-stage respiratory drug; Gisela Schwab, the EVP and chief medical officer at Exelixis, which has produced stellar mid-stage results for cabozantinib; and Susan Molineaux, who headed Proteolix during its mid-stage study for carfilzomib (acquired by Onyx in an $851 million deal) and is now running Calithera.
For most biotechs, Phase II remains right at the crossroads of success and failure. Getting there and navigating all the pitfalls that await any developer in the process is crucial to obtaining critical proof-of-concept data. We'll be looking at new ways to improve your odds of success, leading to the threshold of Phase III and the best possible alliance for your lead products. If you're engaged in clinical trial work, this is one discussion you won't want to miss.
Here's the registration page. Pass it along to your friends and colleagues. In the meantime, look for updates on the breakfast as we get closer to the event. - John Carroll (twitter | email)